https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05764395-2026-09-16 Hipa.ai en 2026-09-16T00:00:00.000Z Pembrolizumab trial in refractory melanoma reports no responses https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct03233347-2026-09-15 Hipa.ai en 2026-09-15T00:00:00.000Z Nivolumab Hodgkin Lymphoma Trial Reports 96.48% PFS https://hipa.ai/drug/atezolizumab/updates/trial-results-posted-nct05908786-2026-09-15 Hipa.ai en 2026-09-15T00:00:00.000Z Atezolizumab Trial Reports HCC Pathologic Response Results https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct06045221-2026-09-15 Hipa.ai en 2026-09-15T00:00:00.000Z Orforglipron cuts HbA1c versus semaglutide in Phase 3 https://hipa.ai/drug/canagliflozin/updates/trial-results-posted-nct04221750-2026-09-14 Hipa.ai en 2026-09-14T00:00:00.000Z Canagliflozin Record Posts Frailty Trial Results in Seniors https://hipa.ai/drug/lurbinectedin/updates/trial-results-posted-nct05229588-2026-09-11 Hipa.ai en 2026-09-11T00:00:00.000Z Lurbinectedin trial reports no responses in advanced GI cancers https://hipa.ai/drug/atezolizumab/updates/trial-results-posted-nct04820179-2026-09-11 Hipa.ai en 2026-09-11T00:00:00.000Z Atezolizumab trial posts pancreatic cancer activity data